Table 1.
Efficacy of different doses of gonadotropin-releasing hormone (GnRH) antagonist at 24 and 52 weeks (150 mg elagolix once daily; 200 mg elagolix twice daily; 75 mg, 100 mg, and 200 mg linzagolix once daily; and 40 mg relugolix plus ABT once daily). NMPP: non-menstrual pelvic pain; * NA: not available. Patients randomized to linzagolix 200 mg were switched to 100 mg linzagolix at week 24).
| Type of Drug | Elagolix | Linzagolix | Relugolix + ABT | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Dose | 150 mg | 200 mg (Twice Daily) |
150 mg | 200 mg (Twice Daily) |
75 mg | 100 mg | 200 mg | 40 mg + ABT | 40 mg + ABT |
| Assessments at Week 12 | |||||||||
| Dysmenorrhea (% responders) | 46.4 | 75.8 | 43.4 | 72.4 | 68.2 | 68.6 | 68.9 | NA | NA |
| NMPP (% responders) | 50.4 | 54.5 | 49.8 | 57.8 | 58.5 | 61.5 | 47.7 | NA | NA |
| Assessments at Week 24 | |||||||||
| Dysmenorrhea (% responders) | 42.1 | 75.3 | 46.2 | 76.9 | 58.3 | 82.1 | 84.1 | 75.5 | 75.2 |
| NMPP (% responders) | 45.7 | 62.1 | 51.6 | 62.2 | 72.9 | 64.1 | 72.7 | 58.5 | 66 |
| Assessments at Week 52 | |||||||||
| Dysmenorrhea (% responders) | 52.1 | 78.1 | 50.8 | 75.9 | 69.2 | 69.2 | 64.7 * | NA | NA |
| NMPP (% responders) | 67.8 | 69.1 | 66.4 | 67.2 | 69.2 | 53.8 | 76.5 * | NA | NA |